The FDA issued a safety announcement warning that the entire class of cyclin-dependent kinase 4/6 (CDK 4/6) inhibitors used to treat some patients with advanced breast cancers may cause rare but severe inflammation of the lungs.
The agency approved new warnings about this risk to be included with the prescribing information and patient package inserts for the entire class of drugs but states that the overall benefit of CDK 4/6 inhibitors is still greater than the risks when these agents